RF. Butterworth. Pathophysiology of hepatic encephalopathy: The concept of synergism.. „Hepatol Res”. 38 (s1The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28-29 September 2007, Iwate, Japan), s. S116-S121, Nov 2008. DOI: 10.1111/j.1872-034X.2008.00436.x. PMID: 19125942.
A. Mas. Hepatic encephalopathy: from pathophysiology to treatment.. „Digestion”. 73 Suppl 1, s. 86-93, 2006. DOI: 10.1159/000089783. PMID: 16498256.
nih.gov
ncbi.nlm.nih.gov
RF. Butterworth. Pathophysiology of hepatic encephalopathy: The concept of synergism.. „Hepatol Res”. 38 (s1The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28-29 September 2007, Iwate, Japan), s. S116-S121, Nov 2008. DOI: 10.1111/j.1872-034X.2008.00436.x. PMID: 19125942.
A. Mas. Hepatic encephalopathy: from pathophysiology to treatment.. „Digestion”. 73 Suppl 1, s. 86-93, 2006. DOI: 10.1159/000089783. PMID: 16498256.
RF. Butterworth. Role of circulating neurotoxins in the pathogenesis of hepatic encephalopathy: potential for improvement following their removal by liver assist devices.. „Liver Int”. 23 Suppl 3, s. 5-9, 2003. PMID: 12950954.
FM. Felaco, P. Pagliano. [Hepatic encephalopathy. Pathogenesis and therapy]. „Infez Med”. 5 (1), s. 14-9, Mar 1997. PMID: 12847306.
Mas A., Rodés J., Sunyer L., Rodrigo L., Planas R., Vargas V., Castells L., Rodríguez-Martínez D., Fernández-Rodríguez C., Coll I., Pardo A. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.. „Journal of hepatology”. 1 (38), s. 51–8, styczeń 2003. PMID: 12480560.
MR. Al Sibae, BM. McGuire. Current trends in the treatment of hepatic encephalopathy.. „Ther Clin Risk Manag”. 5 (3), s. 617-26, Jun 2009. PMID: 19707277.
